HUMAN CANCER BIOLOGY

NIK Controls Classical and Alternative NF-κB Activation and Is Necessary for the Survival of Human T-cell Lymphoma Cells

High Phospho-Stathmin(Serine38) Expression Identifies Aggressive Endometrial Cancer and Suggests an Association with PI3K Inhibition
Elisabeth Wik, Even Birkeland, Jone Trovik, Henrica M.J. Werner, Erling A. Holvik, Siv Mjos, Camilla Krakstad, Kanthida Kusonmano, Karen Mauland, Ingunn M. Stefansson, Frederik Holst, Kjell Petersen, Anne M. Oyan, Ronald Simon, Karl H. Kalland, William Ricketts, Lars A. Akslen, and Helga B. Salvesen

PI3K/AKT Signaling Is Essential for Communication between Tissue-Infiltrating Mast Cells, Macrophages, and Epithelial Cells in Colitis-Induced Cancer

Contents

Highlights of This Issue  2275

SPECIAL FEATURES

CCR Translations

PRAMEing a Picture of Differentiation Therapy for AML?
Robert L. Redner
See article, p. 2562

Classifying MMR Variants: Time for Revised Nomenclature in Lynch Syndrome
Y. Nancy You and Eduardo Vilar
See article, p. 2432

CCR New Strategies

New Strategies in Diagnosing Cancer in Thyroid Nodules: Impact of Molecular Markers
Yuri E. Nikiforov, Linwah Yip, and Marina N. Nikiforova

CCR Perspectives in Drug Approval

U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma
Michael Axelson, Ke Liu, Xiaoping Jiang, Kun He, Jian Wang, Hong Zhao, Dubravka Kufrin, Todd Palmby, Zedong Dong, Anne Marie Russell, Sarah Mikinski, Patricia Keegan, and Richard Pazdur

Molecular Pathways

Molecular Pathways: Radiation-Induced Cognitive Impairment
Dana Greene-Schloesser, Elizabeth Moore, and Mike E. Robbins

Molecular Pathways: Mitogen-Activated Protein Kinase Pathway Mutations and Drug Resistance
Antonia L. Pritchard and Nicholas K. Hayward

Review

Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma
Lipika Goyal, Mandar D. Muzumdar, and Andrew X. Zhu
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2368</td>
<td>Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma</td>
<td>Christina A. von Roemeling, Laura A. Marlow, Johnny J. Wei, Simon J. Cooper, Thomas R. Caulfield, Kevin Wu, Winston W. Tan, Han W. Tun, and John A. Copland</td>
</tr>
<tr>
<td>2393</td>
<td>Inhibition of NF-κB–Mediated Signaling by the Cyclin-Dependent Kinase Inhibitor CR8 Overcomes Prosurvival Stimuli to Induce Apoptosis in Chronic Lymphocytic Leukemia Cells</td>
<td>Emilio Cosimo, Alison M. McCaig, Luke J.M. Carter-Brzezinski, Helen Wheeldon, Michael T. Leach, Karine Le Ster, Christian Berthou, Emilie Durieu, Nassima Ouamata, Hervé Galons, Laurent Meijer, and Alison M. Michie</td>
</tr>
<tr>
<td>2420</td>
<td>Bazedoxifene Exhibits Antiestrogenic Activity in Animal Models of Tamoxifen-Resistant Breast Cancer: Implications for Treatment of Advanced Disease</td>
<td>Suzanne E. Wardell, Erik R. Nelson, Christina A. Chao, and Donald P. McDonnell</td>
</tr>
<tr>
<td>2365</td>
<td>Expression Defect Size among Unclassified MLH1 Variants Determines Pathogenicity in Lynch Syndrome Diagnosis</td>
<td>Inga Hinrichsen, Angela Brieger, Jörg Trojan, Stefan Zeuzem, Mel Nilbert, and Guido Plotz</td>
</tr>
<tr>
<td>2437</td>
<td>Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study</td>
<td>Daniel W. Lin, Lisa F. Newcomb, Elissa C. Brown, James D. Brooks, Peter R. Carroll, Ziding Feng, Martin E. Gleave, Raymond S. Lance, Martin G. Sanda, Ian M. Thompson, John T. Wei, and Peter S. Nelson, for the Canary Prostate Active Surveillance Study Investigators</td>
</tr>
<tr>
<td>2442</td>
<td>PIK3CA Mutation Is Associated with a Favorable Prognosis among Patients with Curatively Resected Esophageal Squamous Cell Carcinoma</td>
<td>Hiroshige Shigaki, Yoshifumi Baba, Masayuki Watanabe, Asu Muraoka, Takatoku Ishimoto, Masaaki Iwatsuki, Shiro Iwagami, Katsuhiko Nosho, and Hideo Baba</td>
</tr>
<tr>
<td>2451</td>
<td>Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas</td>
<td>Qi Zhao, Otavia L. Caballero, Ian D. Davis, Eric Jonasch, Pheroze Tamboli, W.K. Alfred Yung, John N. Weinstein, Kenna Shaw for the TCGA research network, Robert L. Strausberg, and Jun Yao</td>
</tr>
<tr>
<td>2460</td>
<td>Elevated TNFR1 and Serotonin in Bone Metastasis Are Correlated with Poor Survival following Bone Metastasis Diagnosis for Both Carcinoma and Sarcoma Primary Tumors</td>
<td>Antonella Chiechi, Chiara Novello, Giovanna Magagnoli, Emanuel F. Petricoin III, Jianhong Deng, Maria S. Benassi, Piero Picci, Iosif Vaisman, Virginia Espina, and Lance A. Liotta</td>
</tr>
<tr>
<td>2486</td>
<td>Improved Survival with HPV among African Americans with Oropharyngeal Cancer</td>
<td>Maria J. Worsham, Josena K. Stephen, Kang Mei Chen, Meredith Mahan, Vanessa Schweitzer, Shaleta Havard, and George Divine</td>
</tr>
<tr>
<td>Page</td>
<td>Title</td>
<td>Authors</td>
</tr>
<tr>
<td>------</td>
<td>-----------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>2503</td>
<td>Tissue Redox Activity as a Hallmark of Carcinogenesis: From Early to Terminal Stages of Cancer</td>
<td>Rumiana Bakalova, Zhivko Zhelev, Ichio Aoki, and Tsuneo Saga</td>
</tr>
<tr>
<td>2518</td>
<td>Serial Diffusion MRI to Monitor and Model Treatment Response of the Targeted Nanostructure CRLX101</td>
<td>Thomas S.C. Ng, David Wert, Hargun Sohi, Daniel Procissi, David Colcher, Andrew A. Rauhutsczek, and Russell E. Jacobs</td>
</tr>
<tr>
<td>2528</td>
<td>Clinical Correlates of Promoter Hypermethylation of Four Target Genes in Head and Neck Cancer: A Cooperative Group Correlative Study</td>
<td>Jong-Lyel Roh, Xin Victoria Wang, Judith Manola, David Sidransky, Arlene A. Forastiere, and Wayne M. Koch</td>
</tr>
<tr>
<td>2551</td>
<td>Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab</td>
<td>Bertrand Coiffier, Weimin Li, Erin D. Henitz, Jayaprakash D. Karkera, Reyna Favis, Dana Gaffney, Alice Shapiro, Panteli Throcharous, Yusi A. Elsayed, Helgi van de Velde, Michael E. Schaffer, Evgenii A. Osmanov, Xiaonan Hong, Adriana Scheliga, Jiri Mayer, Fritz Offner, Simon Rule, Adriana Teixeira, Joanna Romejko-Jarosinska, Sven de Vos, Michael Crump, Ofer Shpilberg, Pier Luigi Zinzani, Andrew Canaka, Dixie-Lee Esseltine, George Mulligan, and Deborah Ricci</td>
</tr>
<tr>
<td>2562</td>
<td>PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation—A Possible Target for ATRA Response in AML without t(15;17)</td>
<td>Lars Buhlerner, Richard F. Schlenk, Marlies Götz, Ursula Botzenhardt, Susanne Hofmann, Annika C. Russ, Anna Babiak, Lu Zhang, Vanessa Schneider, Konstanze Döhner, Michael Schmitt, Hartmut Döhner, and Jochen Greiner</td>
</tr>
<tr>
<td>2572</td>
<td>FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547</td>
<td>Liang Xie, Xinying Su, Lin Zhang, Xiaolu Yin, Lili Tang, Xiuhua Zhang, Yanping Xu, Zeren Gao, Kunji Liu, Minhua Zhou, Beirong Gao, Danping Shen, Lianhai Zhang, Jiafu JI, Paul R. Gavine, Jingchuan Zhang, Elaine Kilgour, Xiaolin Zhang, and Qunsheng Ji</td>
</tr>
<tr>
<td>2584</td>
<td>Characteristics of Lung Cancers Harboring ARAS Mutations</td>
<td>Kadoaki Ohashi, Lecia V. Sequist, Maria E. Arcila, Christine M. Lovly, Xi Chen, Charles M. Rudin, Teresa Moran, David Ross Camidge, Cindy L. Vnencak-Jones, Lynne Berry, Yumei Pan, Hidefumi Sasaki, Jeffrey A. Engelman, Edward B. Garon, Steven M. Dubinett, Wilbur A. Franklin, Gregory J. Riely, Martin L. Sos, Mark G. Kris, Dora Dias-Santagata, Marc Ladanyi, Paul A. Bunn Jr, and William Pao</td>
</tr>
</tbody>
</table>
ABOUT THE COVER

Assembling of microRNA-loaded transferrin-conjugated-nanoparticles to target acute myeloid leukemia (AML) blasts. The nanoparticle core was composed of negatively charged microRNA molecules (miR) and positively charged polyethylenimine (PEI). Empty nanoparticles were composed of DOPE, linoleic acid, and DMG-PEG. After the loading of the PEI-miR core in the nanoparticles, transferrin-PEG-DSPE was inserted into the nanoparticle surface for specific targeting of leukemia blasts. The background depicts a cytospin of AML blasts derived from a mouse with AML treated with miR-loaded nanoparticles. For details, see the article by Huang and colleagues on page 2355 of this issue.

AC icon indicates Author Choice

CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org

For more information please visit www.aacrjournals.org